Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    "familial hemophagocytic lymphohistiocytosis"
Show Display Options
Rank Status Study
1 Terminated Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: IST and/or alloHCT
2 Recruiting L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Pegaspargase;   Drug: doxorubicin;   Drug: etoposide;   Drug: methylprednisolone
3 Recruiting Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: tocilizumab
4 Completed Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit;   Drug: Etoposide;   Drug: Methotrexate;   Drug: hydrocortisone;   Drug: Dexamethasone
5 Completed The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Intervention:
6 Active, not recruiting Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Dexamethasone;   Drug: Etoposide;   Drug: Cyclosporin;   Procedure: Intrathecal therapy;   Procedure: Stem cell transplant
7 Recruiting L-DEP as an Initial Treatment for EBV-HLH
Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: Pegaspargase;   Drug: doxorubicin hydrochloride liposome injection;   Drug: etoposide;   Drug: methylprednisolone;   Drug: Etoposide;   Drug: dexamethasone
8 Unknown  Trial of DA-EPOCH Regimen for NHL With HLH
Condition: NHL With Hemophagocytic Lymphohistiocytosis
Intervention: Drug: DA-EPOCH
9 Recruiting Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Drug: NI-0501
10 Unknown  Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
Condition: Nonneoplastic Condition
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: dexamethasone;   Drug: etoposide;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: therapeutic hydrocortisone;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
11 Recruiting Treatment of Familiar Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis (HLH)
Interventions: Drug: Alemtuzumab;   Drug: Methyl Prednisolone (MP);   Drug: Cyclosporin A (CSA)
12 Recruiting Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
Condition: Hemophagocytic Lymphohistiocytosis
Intervention: Procedure: splenectomy
13 Completed Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity
Condition: Hemophagocytic Lymphohisticytosis
Intervention: Other: blood sample
14 Recruiting Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Condition: Leukemia
Interventions: Drug: Alemtuzumab;   Drug: Etoposide;   Drug: Dexamethasone;   Drug: Methotrexate;   Behavioral: Phone Call
15 Completed Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)
Conditions: Intensive Care Unit Acquired Paresis;   Muscle Wasting
Intervention: Other: Active muscle stimulation
16 Active, not recruiting Administration of Donor T Cells With the Caspase-9 Suicide Gene
Conditions: Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Non Hodgkin Lymphoma;   Hemophagocytic Lymphohistiocytosis;   Familial Hemophagocytic Lymphohistiocytosis;   Hemophagocytic Syndrome;   Epstein Barr Virus Infection;   X-linked Lymphoproliferative Disease
Interventions: Biological: iCaspase9-transduced T cells;   Drug: AP1903
17 Unknown  Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Conditions: Chediak-Higashi Syndrome;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: filgrastim;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
18 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
19 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
20 Recruiting Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders;   Hemophagocytic Lymphohistiocytosis;   Inherited Bone Marrow Failure Syndrome;   Hemoglobinopathies;   Metabolic Disorders
Intervention: Biological: BPX-501 and AP1903

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.